Morgan Stanley analysts have estimated that Lilly’s GLP-1 pill could bring in as much as $40 billion in annual sales by 2033.

(CNN)– Eli Lilly says it will file for regulatory approval for its GLP1 weight loss pill called Orforglipron. The latest results from a trial of the medication offer enough information for the ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

GLP-1 drugs may lower the risk of some obesity-related cancers, according to an observational study of people who were ...

With those results, Eli Lilly said, it now has the full clinical data package to submit orforglipron to regulators such as the U.S. Food and Drug Administration (FDA). Blockbuster ...

Eli Lilly's GLP-1 pill, orforglipron, shows promising trial results for weight loss and type 2 diabetes. Global regulatory ...

Eli Lilly says its experimental GLP-1 pill, orforglipron, helped people with diabetes lose weight and lower A1C levels.

Eli Lilly says its weight loss pill orforglipron could win approval this year after a trial showed over 10% weight loss in ...

Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight ...

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.

Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its ...

The once-daily pill also helped 75 per cent of patients who received the highest dose of orforglipron lower their A1C level - ...